Intranasal delivery of nanoparticle-based vaccine increases protection against S. pneumoniae
Source abstract
Abstract
Nanoparticle (NP) technologies are becom- ing commonplace in the development of vaccine delivery systems to protect against various diseases. The current study determined the efficacy of intranasal delivery of a 234 ± 87.5 nm poly lactic-co-glycolic acid nanoparticle vaccine construct in establishing protection against experimental respiratory pneumo- coccal infection. Nanoparticles encapsulating heat- killed Streptococcus pneumoniae (NP-HKSP) were retained in the lungs 11 days following nasal adminis- tration compared to empty NP. Immunization with NP- HKSP produced significant resistance against S. pneu- moniae infection compared to administration of HKSP alone. Increased protection correlated with a significant increase in antigen-specific Th1-associated IFN-c cyto- kine response by pulmonary lymphocytes. This study establishes the efficacy of NP-based technology as a non-invasive and targeted approach for nasal-pulmon- ary immunization against pulmonary infections.
Source: openaire · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Pneumonia and Respiratory Infections · Bacterial Infections and Vaccines · Respiratory viral infections research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (26)
Show source-provided references
1. Adam A, Wright A (2009) Mucosal perspectives in pneumococcal vaccine development: a meeting summary. Vaccine 28:2–610.1016/j.vaccine.2009.09.048 ↗
2. Arredouani M, Yang Z, Ning Y et al. (2006) The scavenger receptor MARCO is required for lung defense against pneumococcal pneumonia and inhaled particles. J Exp Med 177
3. Ballester M, Nembrini C, Dhar N et al (2011) Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis. Vaccine 29(40):6959–696610.1016/j.vaccine.2011.07.039 ↗
4. Bogart D, De Groot R, Hermans P (2004) Streptococcus pneumoniae colonisation: the key to pneumococcal disease. Lancet Infect Dis 4:144–15410.1016/S1473-3099(04)00938-7 ↗
5. Camacho AI, de Souza J, Sanchez-Gomez S et al (2011) Mucosal immunization with shigella flexneri outer membrane vesicles induced protection in mice. Vaccine 29(46):8222–822910.1016/j.vaccine.2011.08.121 ↗
6. Cohen JM, Khandavilli S, Camberlein E et al (2011) Protective contributions against invasive Streptococcus pneumoniae pneumonia of antibody and Th17-cell responses to nasopharyngeal colonisation. Plos One. doi:10.1371/journal.pone.002555810.1371/journal.pone.0025558 ↗
7. Derudas M, Brancale A, Naesens L et al (2010) Application of the phosphoramidate ProTide approach to the antiviral drug ribavirin. Bioorg Med Chem 18(7):2748–2755. doi:10.1016/j.bmc.2010.02.01510.1016/j.bmc.2010.02.015 ↗
8. Fattal E, Pecquet S, Couvreur P, Andremont A (2002) Biodegradable microparticles for the mucosal delivery of antibacterial and dietary antigens. Int J Pharm 242(1–2):15–2410.1016/S0378-5173(02)00181-3 ↗
9. Gelperina S, Kisich K, Iseman M, Heifets L (2005) The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med 172(12):1487–149010.1164/rccm.200504-613PP ↗
10. Gupta P, Khatri K, Goyal A, Mishra K, Vyas SP (2007) M-cell targeted biodegradable PLGA nanoparticles for oral immunization against hepatitis B. J Drug Target 15:701–71310.1080/10611860701637982 ↗
11. Gutierro I, Hernandez R, Igartua M, Gascon A, Pedraz J (2002) Size dependent immune response after subcutaneous, oral and intranasal administration of BSA loaded nanoparticles. Vaccine 21(1–2):67–7710.1016/S0264-410X(02)00435-8 ↗
12. Haddadi A, Elamanchili P, Lavasanifar A, Das S. (2007). Delivery of rapamycin by PLGA nanoparticles enhances its suppressive activity on dendritic cells. Wiley Periodicals10.1002/jbm.a.31373 ↗
13. Handsand M, Lowman A (2002) Biodegradable nanoparticles for drug delivery and targeting. Curr Opin Solid State Mater Sci 6:319–32710.1016/S1359-0286(02)00117-1 ↗
14. Heuking S, Borchard G (2012) Toll-like receptor-7 agonist decoration enhances the adjuvanticity of chitosan-DNA nanoparticles. J Pharm Sci 101(3):1166–117710.1002/jps.23017 ↗
15. Hvalbye BK, Aaberge IS, Lovik M et al (1999) Intranasal immunization with heat-inactivated streptococcus pneumoniae protects mice against systemic pneumococcal infection. Infect Immun 67(9):4320–432510.1128/IAI.67.9.4320-4325.1999 ↗
16. Keijzer C, Slutter B, van der Zee R et al (2011) PLGA, PLGA-TMC and TMC-TPP nanoparticles differentially modulate the outcome of nasal vaccination by inducing tolerance or enhancing humoral immunity. Plos One. doi:10.1371/journal.pone.002668410.1371/journal.pone.0026684 ↗
17. Kim BJ, Kayembe K, Simecka JW et al (2011) Corticotropin-releasing hormone receptor-1 and 2 activity produces divergent resistance against stress-induced pulmonary streptococcus pneumoniae infection. J Neuroimmunol 237(1–2):57–65. doi:10.1016/j.jneuroim.2011.06.01610.1016/j.jneuroim.2011.06.016 ↗
18. Kruisbeek AM (2001) Isolation of mouse mononuclear cells. In: Coligan JE et al (eds) Current protocols in immunology chapter 3, unit 3.1. doi:10.1002/0471142735.im0301s3910.1002/0471142735.im0301s39 ↗
19. Lexau C (2005) Changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine. JAMA 294:2043–205110.1001/jama.294.16.2043 ↗
20. Lindell DM, Morris SB, White MP et al (2011) A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. Plos One. doi:10.1371/journal.pone.002182310.1371/journal.pone.0021823 ↗
21. Marriott H, Hellewell P, Cross S et al (2006) Decreased alveolar macrophage apoptosis is associated with increased pulmonary inflammation in a murine model of pneumococcal pneumonia. J Immunol 177(9):6480–648810.4049/jimmunol.177.9.6480 ↗
22. Mukerjee A, Vishwanatha JK (2009) Formulation, characterization and evaluation of curcumin-loaded PLGA nanospheres for cancer therapy. Anticancer Res 29(10):3867–3875
23. Ranjan AP, Zeglam K, Mukerjee A, Thamake S, Vishwanatha JK (2011) A sustained release formulation of chitosan modified PLCL: poloxamer blend nanoparticles loaded with optical agent for animal imaging. Nanotechnology. doi:10.1088/0957-4484/22/29/29510410.1088/0957-4484/22/29/295104 ↗
24. Stano A, van der Vlies AJ, Martino MM et al (2010) PPS nanoparticles as versatile delivery system to induce systemic and broad mucosal immunity after intranasal administration. Vaccine 29(4):804–81210.1016/j.vaccine.2010.11.010 ↗
25. Tan S (2012) Phenotype and function of conventional dendritic cells are not compromised in aged mice. Immunol Cell Biol. doi:10.1038/icb.2011.10410.1038/icb.2011.104 ↗
26. Thamake SI, Raut SL, Ranjan AP, Gryczynski Z, Vishwanatha JK (2011) Surface functionalization of PLGA nanoparticles by non-covalent insertion of a homo-bifunctional spacer for active targeting in cancer therapy. Nanotechnology. doi:10.1088/0957-4484/22/3/03510110.1088/0957-4484/22/3/035101 ↗